Why Is Rezdiffra (Resmetirom) So Hard to Find? [Explained for 2026]

You finally have a diagnosis. Your liver biopsy confirmed MASH (metabolic dysfunction-associated steatohepatitis) with moderate fibrosis — Stage F2 or F3. Your hepatologist writes a prescription for Rezdiffra (resmetirom), the first FDA-approved treatment for your condition. Then you try to fill it. And nothing happens the way you expected.

Your regular pharmacy has no idea what Rezdiffra is. The insurance company wants prior authorization. Weeks pass. This experience — frustrating and confusing — is more common than it should be for a drug that launched in April 2024. Here is exactly why Rezdiffra is difficult to access, and what you can do about it.

Is Rezdiffra Actually in a Shortage?

No — as of 2026, Rezdiffra (resmetirom) is not listed on the FDA drug shortage database. Madrigal Pharmaceuticals has maintained adequate supply since the drug launched. So why can't patients get it easily?

The problem isn't supply. It is access. Rezdiffra faces a set of structural barriers that make it feel like a shortage even when the shelves are technically full. Understanding these barriers is the first step to navigating them.

Barrier #1: Rezdiffra Is a Specialty-Only Drug

Rezdiffra is classified as a Limited Distribution Drug (LDD). This means it is only dispensed through a network of specialty pharmacies — not through CVS, Walgreens, Rite Aid, or your local independent pharmacy. If you walk into a retail pharmacy and ask for it, they will not have it and cannot order it for you.

Specialty pharmacies are different from retail pharmacies. They typically ship medications directly to patients, require enrollment in patient support programs, and work closely with insurance companies and manufacturers. This system is designed for complex, high-cost drugs — but it adds steps and time that patients often don't anticipate.

Barrier #2: Insurance Prior Authorization Requirements

Most commercial insurance plans and Medicare Part D plans require prior authorization (PA) before they will cover Rezdiffra. Your doctor must submit clinical documentation — including your liver biopsy results confirming NASH with F2 or F3 fibrosis — and sometimes a statement that lifestyle interventions have been tried.

This prior authorization process can take days to weeks. Insurers may request additional records, and some initially deny coverage — requiring an appeal from your physician. If you're in a busy hepatology practice, these administrative tasks can create significant delays even before the specialty pharmacy enters the picture.

Barrier #3: Rezdiffra Is Not Covered Like a Typical Drug

With a wholesale acquisition cost of approximately $47,400 per year, Rezdiffra sits on the specialty tier of most drug formularies. Specialty tier copays can range from $50 to $500 or more per fill even for commercially insured patients. For Medicare Part D enrollees, costs can be substantial until the $2,000 annual out-of-pocket cap (effective 2025) is reached.

Some Medicaid programs cover Rezdiffra but may require step therapy — meaning insurers want you to try less expensive interventions first. Each state Medicaid program sets its own rules, adding another layer of variability.

Barrier #4: The Drug Is Still New

Rezdiffra received FDA accelerated approval in March 2024 — making it the first and only pharmacologic treatment for MASH with liver fibrosis at the time of its approval. Because it is the first drug in its class, it is still working its way onto insurance formularies, and payers are still establishing coverage criteria. In the first year after launch, uptake was slower in gastroenterology practices than in hepatology clinics, partly because of education gaps about noninvasive testing and patient identification.

In August 2025, semaglutide (Wegovy) was approved as a second MASH treatment for the same F2-F3 patient population. As the therapeutic landscape grows, insurance coverage criteria and clinical workflows are still catching up.

What Patients Are Actually Experiencing

Here is what the access journey typically looks like for a patient starting Rezdiffra in 2026:

Hepatologist diagnoses MASH F2/F3 via biopsy and prescribes Rezdiffra

Prescription sent to Madrigal Patient Support for enrollment

Insurance prior authorization submitted (can take 1–3 weeks)

If approved, prescription routed to a specialty pharmacy in the network

Specialty pharmacy verifies insurance and copay card enrollment

Medication shipped — no pickup at local pharmacy possible

From prescription to first dose, the process can take anywhere from a few days (for straightforward commercial insurance cases) to several weeks (when prior auth is denied and appealed). Each step is a potential delay point.

What You Can Do to Speed Up Access

There are several concrete steps you can take to reduce delays:

Enroll in Madrigal Patient Support immediately — call 877-219-7770 as soon as your prescription is written. They navigate the specialty pharmacy and insurance process.

Ask your doctor about the prior auth paperwork — make sure your biopsy results and chart notes are ready to submit. Delays often happen when documentation is missing.

If your PA is denied, appeal — your hepatologist can write a letter of medical necessity. First-time denials are not the end of the road.

Apply for the Madrigal Copay Savings Card — commercially insured patients may pay as little as $0/month. Visit copay.rezdiffra.com.

How medfinder Can Help

While Rezdiffra is a specialty pharmacy drug, navigating the system still requires knowing who has your medication and where to turn. medfinder helps patients find medications in stock near them by calling pharmacies on their behalf. If you're wondering where to start or which specialty pharmacy in your area carries Rezdiffra, medfinder can help you get answers faster than calling around yourself.

For more specific steps on locating Rezdiffra, see our guide: How to Find Rezdiffra in Stock Near You (Tools + Tips).

The Bottom Line

Rezdiffra is not in a drug shortage. The supply is there. But the access pathway — specialty-only distribution, prior authorization, specialty tier pricing, and a still-maturing prescribing infrastructure — creates real friction for patients who need it. Understanding these barriers, and knowing who to call and what to ask, dramatically improves your chances of getting your prescription filled quickly and affordably.